Trial reportBMC anesthesiology2025
Esketamine as an opioid-sparing adjuvant for epidural labour analgesia: a randomised, double-blind trial evaluating postpartum depression.
Trial report in BMC anesthesiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Epidural analgesia supplemented with lidocaine reduces maternal fever during labor: a randomized controlled trial.Frontiers in pharmacology · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundOpioid-based epidural analgesia, while effective, is frequently associated with maternal side effects such as pruritus and potential central sensitisation. Esketamine provides rapid analgesic and antidepressant effects at subanesthetic doses. We compared esketamine with sufentanil both added to 0.083% ropivacaine focusing on efficacy, maternal safety, and postpartum depression outcomes.
methodsIn this single-centre, randomised, double-blind, controlled trial, 200 nulliparous parturients (ASA I-II, 18-40 years, cervical dilatation 2-3 cm) requesting epidural analgesia were equally allocated to receive patient-controlled epidural analgesia (PCEA) containing either sufentanil 0.3 µg/ml or esketamine 0.3 mg/ ml combined with ropivacaine 0.083%. Primary outcomes included analgesic onset time, maximum sensory block level and Edinburgh Postnatal Depression Scale (EPDS) at 42 days postpartum. Secondary outcomes included adverse events, VAS scores and neonatal Apgar scores.
resultsBetween December 2024 and May 2025, 197 participants completed the study (98 of sufentanil, 99 of esketamine). Baseline characteristics were comparable. Esketamine significantly reduced onset time (5.9 ± 0.6 min vs. 9.8 ± 1.7 min, P < 0.001), achieved a predominant T8 sensory block (67.7% vs. 45.9%, P < 0.001) and lowered EPDS scores (5.6 ± 1.3 vs. 9.8 ± 1.5, P < 0.001). Total ropivacaine consumption throughout the first stage of labour was 17% lower in the esketamine group (12.4 ml [10.3-14.5] vs. 14.9 ml [12.6-17.2]; P < 0.001). EPDS scores at 42 days were lower with esketamine (5.6 ± 1.3 vs. 9.8 ± 1.5, P < 0.001). The incidence of probable postpartum depression (EPDS ≥13) was also reduced in the esketamine group (4.0% vs. 18.4%, P = 0.003). Maternal adverse events such as pruritus (3.0% vs. 45.9%), hypotension (4.0% vs. 38.8%), and urinary retention (3.0% vs. 22.4%) were markedly reduced with esketamine (all P < 0.001). VAS and Apgar scores were similar between groups.
conclusionsEsketamine-ropivacaine epidural analgesia provides faster onset, fewer maternal side effects, and potential antidepressant benefits compared with sufentanil-ropivacaine. These findings support esketamine as a promising opioid-sparing strategy in obstetric anaesthesia.
trial registrationChinese Clinical Trial Registry, ChiCTR2500109086. Retrospectively registered on September 11, 2025.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.